Anna C Pavlick
Overview
Explore the profile of Anna C Pavlick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
8776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stephan C, Al Assaad M, Levine M, Deshpande A, Sigouros M, Manohar J, et al.
Pathol Res Pract
. 2024 Oct;
263:155668.
PMID: 39427588
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine neoplasm of the skin. Immunosuppression, ultraviolet radiation and the integration of Merkel cell polyomavirus (MCPyV) have all been shown to be involved...
2.
Moser J, Bhatia S, Amin A, Pavlick A, Betts K, Du E, et al.
Cancer Immunol Immunother
. 2024 May;
73(7):116.
PMID: 38713408
Objectives: Nivolumab is approved as adjuvant therapy for resected stage III/IV melanoma based on the phase 3 CheckMate 238 trial. This analysis compared outcomes from CheckMate 238 with those from...
3.
Pavlick A, Ariyan C, Buchbinder E, Davar D, Gibney G, Hamid O, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37852736
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant...
4.
Rasco D, Medina T, Corrie P, Pavlick A, Middleton M, Lorigan P, et al.
Cancer Chemother Pharmacol
. 2023 May;
92(1):15-28.
PMID: 37219686
Purpose: Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors. Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan‑RAF inhibitor....
5.
Ramos A, Giantini-Larsen A, Pannullo S, Brandmaier A, Knisely J, Magge R, et al.
Neurooncol Adv
. 2022 Dec;
4(1):vdac176.
PMID: 36532509
The incidence of brain metastases continues to present a management issue despite the advent of improved systemic control and overall survival. While the management of oligometastatic disease (ie, 1-4 brain...
6.
Silk A, Barker C, Bhatia S, Bollin K, Chandra S, Eroglu Z, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35902131
Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic...
7.
Weber J, Levinson B, Laino A, Pavlick A, Woods D
Melanoma Res
. 2022 Jun;
32(5):324-333.
PMID: 35678233
Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%. Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances...
8.
Berger A, Bernstein K, Alzate J, Mullen R, Silverman J, Sulman E, et al.
J Neurooncol
. 2022 Jun;
158(3):471-480.
PMID: 35665462
Purpose: New therapies for melanoma have been associated with increasing survival expectations, as opposed to the dismal outcomes of only a decade ago. Using a prospective registry, we aimed to...
9.
Bhardwaj N, Friedlander P, Pavlick A, Ernstoff M, Gastman B, Hanks B, et al.
Nat Cancer
. 2022 Feb;
1(12):1204-1217.
PMID: 35121932
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment enhancement of responses to dendritic cell (DC)-targeting...
10.
Rabinowits G, Migden M, Schlesinger T, Ferris R, Freeman M, Guild V, et al.
JID Innov
. 2021 Dec;
1(4):100045.
PMID: 34909742
Cutaneous squamous cell carcinoma is the second most common skin cancer in the United States. Currently, there is no standardized management approach for patients with cutaneous squamous cell carcinoma who...